Where does Dasman Diabetes Institute rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Dasman Diabetes Institute ranks #39,752 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Dasman Diabetes Institute hold?

Dasman Diabetes Institute holds 6 US utility patents granted between 2020 and 2025, spanning 9 technology areas.

What is Dasman Diabetes Institute's Innovation Score?

Dasman Diabetes Institute has an Innovation Score of 25.2 out of 100 (17th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Dasman Diabetes Institute's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Dasman Diabetes Institute.

What does claim depth mean for Dasman Diabetes Institute's patents?

Dasman Diabetes Institute's patents average 10.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Dasman Diabetes Institute patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Dasman Diabetes Institute

Q: What technology areas does Dasman Diabetes Institute focus on?

Dasman Diabetes Institute's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 4 patents. Grants appear in 9 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 9 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Dasman ranks #39,752 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 9 technology areas.

#39,752
of 49,997 US assignees by volume: 17th percentile
by Innovation Score (25.2/100): 10.3
avg claims per patent

USPTO PatentsView assignee plate

Corpus R39752 · Foreign Corporation #39,752 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #39,752/49,997
PHOTO-FINISH Daisy Intelligence
CPC-NARROW A61P · 9 areas
INNOV-THIN 25.2/100
CLAIMS-PAR 10.3 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Daisy Intelligence Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Anhui New Star… · near

25
Poulsen Roser A/S · near

25
Dasman Diabetes… · this assignee

25
Quantum Genomics · near

25
Lucent Sky · near

25
3D Lighting… · lowest

7

What this shows Dasman's Innovation Score is 25.2/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Dasman's grants concentrate

Dasman Diabetes Institute is a focused PatentsView assignee: 9 CPC subclasses with 66.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2023. By volume, Dasman sits between Daisy Intelligence Corporation and Daystar Products International, Inc..

Dasman's three-year grant acceleration

Dasman Diabetes Institute shows 1 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Daisy Intelligence

6
Damoatech

6
Danal

6
Danbury Mission

6
Datalogix Holdings

6
David Yurman IP

6
Dawg'n Around

6
Daystar Products…

6
Dasman Diabetes I… ◀

6

What this shows Dasman holds 6 patents at rank #39,826, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Dasman

By rank, the assignees closest to #39,826 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Dasman's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Dasman, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (25 here).

Quantum Genomics 25 Anhui New Star Pharmaceutical Development Co., Ltd 25 Poulsen Roser A/S 25 Lucent Sky Corporation 25

Dasman's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 17th percentile higher than 17% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Dasman Diabetes Institute patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	33.3%
2021	2	33.3%
2023	1	16.7%
2025partial year	1	16.7%

Which technologies does Dasman Diabetes Institute patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

A61B - DIAGNOSIS; SURGERY; Identification 1

C12Y - Enzymes 1

C07K - Peptides 1

C07D - Heterocyclic Compounds 1

Top 9 of 9 technology areas

Where it ranks

Overall rank by patents

#39,752

of 49,997 tracked assignees

Innovation Score

25.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Dasman Diabetes Institute's patent record in context - here's where to go next.

Dasman Diabetes Institute's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 66.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #39,752 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Dasman Diabetes Institute against Daisy Intelligence Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 25.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.